The Cardiff Acne Disability Index (CADI) is a questionnaire designed to measure the quality of life (QoL) of teenagers and young adults with acne. It has been used clinically and …
Chronic Adverse Effects From Anti-PD-1 Immunotherapies Common
About 43 percent of patients who receive anti-PD1 therapy for advanced melanoma have chronic immune-related adverse effects
Nearly Half of Older Adults Use Online Physician Ratings
Online ratings perceived to be very important nearly as often as word-of-mouth recommendations from family and friends
Excoriation (skin-picking) disorder among adolescents and young adults with acne-induced postinflammatory hyperpigmentation and scars.
A plethora of health-related concerns, including skin disorders, are particularly common during the critical periods of adolescence and young adulthood. Their reactions to skin-related disorders can be different from their …
Children With Worse Atopic Dermatitis More Likely to Have Learning Disabilities
Findings independent of socioeconomic characteristics, onset age, and other related disorders
Onychomycosis in patients with multiple sclerosis: prevalence, clinical description, mycological, and dermoscopic study in a Mexican population.
Multiple sclerosis (MS) is a chronic demyelinating disease related to HLA-DR8. Susceptibility to onychomycosis has been found in Mexican mestizos with HLA-DR8. The frequency of onychomycosis in this neurological disease …
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial.
The European Organisation for Research and Treatment of Cancer (EORTC) 1325/KEYNOTE-054 trial assessed pembrolizumab versus placebo in patients with resected high-risk stage III melanoma. At 15-month median follow-up, pembrolizumab improved …
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial.
The European Organisation for Research and Treatment of Cancer (EORTC) 1325-MG/KEYNOTE-054 trial in patients with resected, high-risk stage III melanoma demonstrated improved recurrence-free survival with adjuvant pembrolizumab compared with placebo …
Microneedling as an adjuvant to topical therapies for melasma: A systematic review and meta-analysis.
Microneedling as an adjuvant to topical medications has shown promising but variable results in the treatment of melasma.To conduct a systematic review and meta-analysis on the efficacy of topical therapy …
In-Vitro Diagnostics for the Medical Dermatologist: Part 1: Autoimmune Tests.
Despite the expansion of available in-vitro laboratory tests at a rate far exceeding that of dermatological pharmaceuticals, the existing literature is dominated by discussion of the latter. With the advent …